StockNews.com Initiates Coverage on TherapeuticsMD (NASDAQ:TXMD)

StockNews.com began coverage on shares of TherapeuticsMD (NASDAQ:TXMD) in a research report issued to clients and investors on Tuesday. The firm set a “hold” rating on the stock.

TherapeuticsMD Trading Up 1.6 %

TherapeuticsMD stock opened at $1.78 on Tuesday. TherapeuticsMD has a one year low of $1.43 and a one year high of $3.72. The stock has a 50-day moving average of $1.76 and a two-hundred day moving average of $1.98.

TherapeuticsMD (NASDAQ:TXMD) last released its earnings results on Monday, August 12th. The company reported ($0.09) EPS for the quarter. The company had revenue of $0.23 million for the quarter.

Institutional Inflows and Outflows

A number of hedge funds have recently modified their holdings of TXMD. Prosperity Consulting Group LLC acquired a new position in shares of TherapeuticsMD in the 1st quarter valued at $56,000. ADAR1 Capital Management LLC acquired a new position in shares of TherapeuticsMD in the fourth quarter worth about $612,000. Finally, Clearline Capital LP boosted its stake in shares of TherapeuticsMD by 18.9% during the 2nd quarter. Clearline Capital LP now owns 636,622 shares of the company’s stock worth $1,025,000 after acquiring an additional 101,282 shares in the last quarter. 30.74% of the stock is owned by institutional investors and hedge funds.

TherapeuticsMD Company Profile

TherapeuticsMD, Inc operates as a pharmaceutical royalty company in the United States. It has a license agreement with Mayne Pharma to commercialize the IMVEXXY, BIJUVA, and ANNOVERA prescription prenatal vitamin products sold under the BocaGreenMD and vitaMedMD brand names. The company sells its prescription pharmaceutical products and prenatal vitamin products through wholesale distributors and retail pharmacy distributors.